Completed PHASE2 INTERVENTIONAL NCT00123851

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer

Sponsor: Beth Israel Deaconess Medical Center

Conditions Colorectal Cancer Neoplasm Metastasis

Interventions Capecitabine Oxaliplatin Tarceva (OSI-774)

Updated 5 times since 2017 Last updated: Apr 27, 2009 Started: Mar 31, 2003 Primary completion: Aug 31, 2006 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00123851, this PHASE2 trial focuses on Colorectal Cancer and Neoplasm Metastasis and remains completed. Sponsored by Beth Israel Deaconess Medical Center, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Genentech, Inc.
Hoffmann-La Roche
Massachusetts General Hospital
OSI Pharmaceuticals
Sanofi-Synthelabo

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States